MILD-MT
(2026)Objective
PROBE RCT testing whether EVT improves 90-day functional outcome in patients with mild LVO stroke (NIHSS <6) and a favorable perfusion mismatch profile compared with best medical management.
Study Summary
• Primary 90-day mRS 0-1: 69.4% vs 50.0%, RR 1.39 (1.14-1.70).
• 90d mRS 0-2: 82.6% vs 66.9% (sig).
• sICH at 48h 2.1% vs 1.9% (NS); 90d mortality 0.7% vs 0.0% (NA).
• END within 7d: 13.9% vs 31.4% (sig).
• 90d mRS 0-2: 82.6% vs 66.9% (sig).
• sICH at 48h 2.1% vs 1.9% (NS); 90d mortality 0.7% vs 0.0% (NA).
• END within 7d: 13.9% vs 31.4% (sig).
Intervention
EVT (stenting/angioplasty allowed) vs best medical management (BMM); rescue EVT allowed in 8.3% of BMM
Inclusion Criteria
China. NIHSS <6 at randomization; ICA-IC/M1/M2 (with or without ICA-EC) occlusion; within 24 h, ASPECTS >=6; perfusion mismatch (core <=50 mL, Tmax >6s lesion >50 mL). Excluded 25% of otherwise eligible patients.
Study Design
Arms: EVT vs best medical management
Patients per Arm: EVT n=144 vs BMM n=156 (total 300)
Outcome
• Primary 90-day mRS 0-1: 69.4% vs 50.0%, RR 1.39 (1.14-1.70).
• 90d mRS 0-2: 82.6% vs 66.9% (sig).
• sICH at 48h: 2.1% vs 1.9% (NS).
• 90d mortality: 0.7% vs 0.0% (NA).
• END within 24h: 6.3% vs 10.7% (NS); within 7d: 13.9% vs 31.4% (sig).
• 90d mRS 0-2: 82.6% vs 66.9% (sig).
• sICH at 48h: 2.1% vs 1.9% (NS).
• 90d mortality: 0.7% vs 0.0% (NA).
• END within 24h: 6.3% vs 10.7% (NS); within 7d: 13.9% vs 31.4% (sig).